MX9708977A - Uso de r-enantiomero de sales de n-propargilo-1-aminoindano, y composiciones de las mismas. - Google Patents

Uso de r-enantiomero de sales de n-propargilo-1-aminoindano, y composiciones de las mismas.

Info

Publication number
MX9708977A
MX9708977A MX9708977A MX9708977A MX9708977A MX 9708977 A MX9708977 A MX 9708977A MX 9708977 A MX9708977 A MX 9708977A MX 9708977 A MX9708977 A MX 9708977A MX 9708977 A MX9708977 A MX 9708977A
Authority
MX
Mexico
Prior art keywords
aminoindan
propargyl
subject invention
subject
pharmaceutically acceptable
Prior art date
Application number
MX9708977A
Other languages
English (en)
Inventor
Moussa B H Youdim
John P M Finberg
Ruth Levy
Jeffrey Sterling
David Lerner
Haim Yellin
Alex Veinberg
Original Assignee
Teva Pharma
Technion Res And Dev
Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23772591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9708977(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma, Technion Res And Dev, Foundation Ltd filed Critical Teva Pharma
Publication of MX9708977A publication Critical patent/MX9708977A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion proporciona R (+) -N-propargilo-1-aminoindano y la sales farmacéuticamente aceptables del mismo, así como una composicion farmacéuticamente que contiene el mismo. La invencion de la materia también proporciona métodos para tratar a un sujeto afligido con la enfermedad de Parkinson, con un desorden de memoria, con demencia, con depresion, con síndrome hiperactivo, con una enfermedad efectiva, con una enfermedad neurodegenerativa, con una lesion neurotoxica, con una apoplejía, con isquemia del cerebro, con una lesion de trauma de cabeza, con una lesion de trauma espinal, con un neurotrama, con esquisofrenia, y con un desorden de déficit de atencion, de multiple esclerosis o síntomas de retiro, usando R (+) -N-propargilo-1-aminoindano o las sal farmacéuticamente aceptable de la invencion de la materia. La invencion de la materia además proporciona un método para evitar el daño al nervio en el sujeto. Finalmente, la invencion de la materia proporciona métodos para preparar R (+) -N-propargilo-1-aminoindano, una sal del mismo, y N-propargilo-1-aminoindano racémico.
MX9708977A 1995-05-22 1996-05-22 Uso de r-enantiomero de sales de n-propargilo-1-aminoindano, y composiciones de las mismas. MX9708977A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/446,439 US5744500A (en) 1990-01-03 1995-05-22 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
PCT/US1996/007465 WO1996037199A1 (en) 1995-05-22 1996-05-22 Use of r-enantiomer of n-propargyl-1-aminoindan, salts, and compositions thereof

Publications (1)

Publication Number Publication Date
MX9708977A true MX9708977A (es) 1998-03-31

Family

ID=23772591

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9708977A MX9708977A (es) 1995-05-22 1996-05-22 Uso de r-enantiomero de sales de n-propargilo-1-aminoindano, y composiciones de las mismas.

Country Status (22)

Country Link
US (6) US5744500A (es)
EP (1) EP0828485A4 (es)
JP (1) JP3341898B2 (es)
KR (1) KR100412154B1 (es)
CN (1) CN1096853C (es)
AU (1) AU699090B2 (es)
BR (1) BR9608733A (es)
CA (1) CA2221458A1 (es)
CZ (1) CZ288724B6 (es)
EE (1) EE03741B1 (es)
HK (1) HK1015269A1 (es)
HU (1) HUP9901629A3 (es)
IL (1) IL118247A (es)
LT (1) LT4455B (es)
LV (1) LV12083B (es)
MX (1) MX9708977A (es)
NO (1) NO975331L (es)
NZ (1) NZ308866A (es)
PL (1) PL184124B1 (es)
RU (1) RU2203653C2 (es)
SK (1) SK283675B6 (es)
WO (1) WO1996037199A1 (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5914349A (en) * 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5726969A (en) * 1994-12-28 1998-03-10 Matsushita Electric Industrial Co., Ltd. Optical recording medium having dual information surfaces
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
AU775885B2 (en) 1999-10-27 2004-08-19 Teva Pharmaceutical Industries Ltd. Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
WO2003039525A1 (en) 2001-11-05 2003-05-15 Krele Pharmaceuticals Llc Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
EP1565185A4 (en) * 2002-11-07 2011-01-05 Technion Res & Dev Foundation NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
ES2588780T3 (es) * 2002-11-15 2016-11-04 Teva Pharmaceutical Industries Limited Uso de rasagilina con o sin riluzol para el tratamiento de la esclerosis lateral amiotrófica
US20040176430A1 (en) * 2002-11-21 2004-09-09 Jeffrey Sterling Propargyl-trifluoromethoxy-amino-benzothiazole derivatives
CN1605336A (zh) * 2003-10-10 2005-04-13 中国医学科学院药物研究所 左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
EP1686973A4 (en) * 2003-11-25 2009-03-25 Technion Res & Dev Foundation COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISEASES
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
US20050197365A1 (en) * 2004-02-27 2005-09-08 Jeffrey Sterling Diamino thiazoloindan derivatives and their use
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
WO2006014968A2 (en) * 2004-07-27 2006-02-09 Teva Pharmaceutical Industries, Ltd. Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
US20060025446A1 (en) * 2004-07-27 2006-02-02 Jeffrey Sterling Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
RS52867B (en) * 2005-02-17 2013-12-31 Teva Pharmaceutical Industries Ltd. GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
MX2007010233A (es) 2005-02-23 2007-11-07 Teva Pharma Formulaciones de rasagilina de uniformidad de contenido mejorada.
JP2008531594A (ja) * 2005-02-24 2008-08-14 テバ ファーマシューティカル インダストリーズ リミティド 酒石酸ラドスチジルの製剤
EP1885388B1 (en) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Treating and evaluating inflammatory disorders
US20060276537A1 (en) * 2005-06-01 2006-12-07 Tamar Goren Use of ladostigil for the treatment of multiple sclerosis
FR2886549B1 (fr) * 2005-06-06 2007-09-07 Biocodex Composition pharmaceutique destinee a la prevention ou au traitement des oedemes cerebraux
US8263655B2 (en) * 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
EP1954667B1 (en) 2005-11-17 2017-02-08 Teva Pharmaceutical Industries Ltd Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
US20070135518A1 (en) * 2005-12-09 2007-06-14 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
WO2007070425A2 (en) * 2005-12-09 2007-06-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of low-dose ladostigil for neuroprotection
US20110047685A1 (en) * 2006-02-16 2011-03-03 Ferrara Vincent R Impact energy management method and system
WO2007098264A2 (en) 2006-02-21 2007-08-30 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
CA2646250A1 (en) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
CN101062897B (zh) * 2006-04-25 2011-11-23 重庆医药工业研究院有限责任公司 一种制备2，3-二氢-1h-茚-1-胺及其衍生物的改进方法
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
JP5623081B2 (ja) * 2006-12-14 2014-11-12 テバ ファーマシューティカル インダストリーズ リミティド 結晶質固体のラサジリン塩基
AU2007334493B2 (en) 2006-12-14 2010-12-02 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
EP2194780A4 (en) * 2007-09-05 2010-10-27 Teva Pharma METHOD FOR TREATING GLAUCOMA BY RASAGILINE
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
NZ586025A (en) * 2008-01-11 2012-08-31 Teva Pharma Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
EP2276722A2 (en) * 2008-03-28 2011-01-26 Medichem, S.A. Polymorphic form of an aminoindan mesylate derivative
CA2723870C (en) * 2008-06-02 2015-04-21 Generics [Uk] Limited An improved process for the preparation of amines
CA2723869C (en) * 2008-06-02 2013-07-16 Generics [Uk] Limited A process for the preparation of enantiomerically pure amines
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
JP2011522892A (ja) * 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
BRPI0909997A2 (pt) 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
WO2011012140A2 (en) 2008-07-11 2011-02-03 Synthon Bv Polymorphs of rasagiline hydrochloride
WO2010013048A1 (en) * 2008-07-30 2010-02-04 Generics [Uk] Limited Polymorphic form of rasagiline mesylate
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
JP2012523393A (ja) * 2009-04-09 2012-10-04 エム・エス・ディー・オス・ベー・フェー インダン誘導体
JP2012532843A (ja) 2009-07-09 2012-12-20 ラティオファーム ゲーエムベーハー ラサギリンの塩およびその製剤
CN102048717B (zh) † 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2325159A1 (en) 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Novel salts of rasagiline
US8741962B2 (en) * 2009-11-26 2014-06-03 Usv Limited Process for preparation of Rasagiline and salts thereof
AU2010341499A1 (en) 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan
EP3517103A1 (en) 2010-02-03 2019-07-31 Pharma Two B Ltd. Extended release formulations of rasagiline and uses thereof
UA103851C2 (en) 2010-04-30 2013-11-25 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Propylaminoindan transdermal composition
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
CA2806740A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
EP2611440B1 (en) 2010-09-01 2017-02-01 Tonix Pharmaceuticals, Inc. Treatment for cocaine addiction
JP2014503480A (ja) 2010-10-26 2014-02-13 テバ ファーマシューティカル インダストリーズ リミティド ジュウテリウムリッチなラサギリン
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
EP2688561B1 (en) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
AU2012323349A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-formyl-propargyl-aminoindan
BR112014008552A2 (pt) * 2011-10-10 2017-04-18 Teva Pharma r(+)-n-metil-propargilaminoindano
EP2776020B1 (en) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Methods for the treatment of skin neoplasms
EA201491734A1 (ru) 2012-03-21 2015-01-30 Синтон Бв Стабилизированные фармацевтические композиции, содержащие соли разагилина
WO2013175493A1 (en) 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤
EA031621B1 (ru) 2012-11-02 2019-01-31 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Трансдермальная композиция на основе пропиниламиноиндана, содержащий такие композиции набор и способ доставки пропиниламиноиндана
ES2524865T1 (es) * 2013-02-06 2014-12-15 Galenicum Health S.L. Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata
ES2502140T1 (es) * 2013-02-06 2014-10-02 Galenicum Health S.L. Comprimidos de liberación inmediata de rasagilina hemitartrato
WO2014141280A1 (en) * 2013-03-13 2014-09-18 Abital Pharma Pipelines Ltd. Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease
CN103804200B (zh) * 2014-02-21 2015-04-29 常州市第四制药厂有限公司 雷沙吉兰及其类似物的制备方法
CN113924086A (zh) * 2019-04-17 2022-01-11 维奇健康科学有限责任公司 液体药物组合物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US513244A (en) * 1894-01-23 Island
US3201470A (en) * 1965-08-17 Chsx c cech
US3253037A (en) * 1962-06-19 1966-05-24 Ciba Geigy Corp N-2-alkynyl-amino-benzocylo-alkanes
GB1187017A (en) 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
GB1037014A (en) 1963-08-02 1966-07-20 Aspro Nicholas Ltd Derivatives of 1-aminoindane
US3513249A (en) * 1968-12-24 1970-05-19 Ideal Ind Explosion connector with improved insulating means
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
ATE76747T1 (de) * 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
ES2052593T3 (es) 1986-08-21 1994-07-16 Roussel Uclaf Procedimiento para preparar derivados del indano.
HU197510B (en) 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4855326A (en) * 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
ZA885824B (en) 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
FR2626877B1 (fr) 1988-02-05 1991-04-05 Delalande Sa Ethers alkyliques ou benzyliques du phenol, leurs procedes de preparation et leur application en therapeutique
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
GB8909793D0 (en) 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
CA2067123A1 (en) 1989-09-25 1991-03-26 Esther M. Sternberg Evaluative means for detecting inflammatory reactivity and for predicting response to stress
ES2097155T3 (es) 1989-10-02 1997-04-01 Cima Labs Inc Forma de dosificacion efervescente y metodo de administracion.
FR2655044B1 (fr) 1989-11-24 1995-03-03 Delalande Sa Derives d'(hetero) arylmethyloxy-4 phenyl tetrazole et oxadiazole, leur procede de preparation et leur application en therapeutique.
JPH03176457A (ja) 1989-12-04 1991-07-31 Nippon Paint Co Ltd 新規プロパルギル化合物、その製法ならびに該化合物を含む被覆材
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
CA2039742A1 (en) 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials
US5169868A (en) 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5767164A (en) * 1991-04-04 1998-06-16 Innovations Foundation Use of deprenyl to rescue damaged nerve cells
IL112819A (en) 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
KR100256147B1 (ko) * 1991-12-24 2000-08-01 오노다 마사요시 구강내 붕해성 제제 및 이의 제조방법
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
AU4534593A (en) 1992-06-12 1994-01-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
SE501848C2 (sv) 1992-11-18 1995-06-06 Kvaerner Pulping Tech Metod att koka massa kontinuerligt vid konstant temperatur
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL112779A (en) 1994-03-01 1999-11-30 Gergely Gerhard Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
CN1171586C (zh) 1995-03-02 2004-10-20 R·P·舍雷尔有限公司 包含单胺氧化酶b抑制剂的药物组合物
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
AU2472499A (en) * 1998-01-27 1999-08-09 Thomas N. Thomas Methods of treatment using mao-a and mao-b inhibitors such as l-deprenyl
FI104042B1 (fi) * 1998-09-29 1999-11-15 Aaro Kiuru Menetelmä keuhkojen perfuusion mittaamiseksi
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PL370793A1 (en) * 2001-07-04 2005-05-30 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20060009483A1 (en) * 2002-05-31 2006-01-12 Bayer Pharmaceuticals Corporation Compounds and compositions for the treatment of diabetes and diabetes-related disorders
AU2003288902A1 (en) * 2002-09-06 2004-04-08 Genteric, Inc. Microcapsules and methods of use
ES2588780T3 (es) * 2002-11-15 2016-11-04 Teva Pharmaceutical Industries Limited Uso de rasagilina con o sin riluzol para el tratamiento de la esclerosis lateral amiotrófica
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
MX2007010233A (es) * 2005-02-23 2007-11-07 Teva Pharma Formulaciones de rasagilina de uniformidad de contenido mejorada.

Also Published As

Publication number Publication date
AU699090B2 (en) 1998-11-19
RU2203653C2 (ru) 2003-05-10
HUP9901629A2 (hu) 2000-02-28
IL118247A0 (en) 1996-09-12
NZ308866A (en) 1999-09-29
CA2221458A1 (en) 1996-11-28
EE03741B1 (et) 2002-06-17
US20030065038A1 (en) 2003-04-03
NO975331D0 (no) 1997-11-20
PL184124B1 (pl) 2002-09-30
WO1996037199A1 (en) 1996-11-28
KR19990021896A (ko) 1999-03-25
NO975331L (no) 1998-01-20
KR100412154B1 (ko) 2004-07-05
SK283675B6 (sk) 2003-11-04
US6316504B1 (en) 2001-11-13
EP0828485A1 (en) 1998-03-18
HK1015269A1 (en) 1999-10-15
EP0828485A4 (en) 1998-12-02
US5744500A (en) 1998-04-28
US20030212145A1 (en) 2003-11-13
AU5872396A (en) 1996-12-11
SK157497A3 (en) 1998-05-06
HUP9901629A3 (en) 2000-03-28
CN1096853C (zh) 2002-12-25
US20070100001A1 (en) 2007-05-03
EE9700310A (et) 1998-06-15
US6956060B2 (en) 2005-10-18
IL118247A (en) 2002-07-25
JP2000508292A (ja) 2000-07-04
LT4455B (lt) 1999-01-25
JP3341898B2 (ja) 2002-11-05
US20060094783A1 (en) 2006-05-04
WO1996037199A8 (en) 1999-08-12
LT97200A (en) 1998-09-25
BR9608733A (pt) 1999-12-07
CZ369997A3 (cs) 1999-06-16
LV12083A (lv) 1998-07-20
LV12083B (en) 1998-09-20
US6630514B2 (en) 2003-10-07
CZ288724B6 (cs) 2001-08-15
PL323470A1 (en) 1998-03-30
CN1191481A (zh) 1998-08-26

Similar Documents

Publication Publication Date Title
MX9708977A (es) Uso de r-enantiomero de sales de n-propargilo-1-aminoindano, y composiciones de las mismas.
MXPA94008019A (es) R-enantiomero de n-propargilo-1-aminoindano, sales, composiciones y usos de los mismos.
IL118836A0 (en) Pharmaceutical compositions comprising S-(-)N-propargyl-1-aminoindan
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
CA2031714A1 (en) R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
CA2171882A1 (en) Inhibitors of .beta.-amyloid protein production
CA2119511A1 (en) Benzimidazole compounds, their use and preparation
IL96146A0 (en) Method of treating anxietyrelated disorders using sertraline
WO2003041646A3 (en) L-dopa ethyl ester salts and uses thereof
NO306509B1 (no) Pyrimidinderivater, anvendelse derav og farmasöytisk preparat
MX9605218A (es) Amidas aciclicas y ciclicas novedosas como mejoradores de liberacion de neurotransmisores.
AU3585089A (en) Condensed diazepinones
AU653802B2 (en) Condensed diazepinones